High-flow nasal oxygen during sedated stomach and food pipe endoscopy in people with COPD
Tests whether high-flow nasal oxygen lowers low oxygen levels during sedated endoscopy in COPD.
Plain-language title generated from the registry record
Registry title: High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang University
- Trial code
- NCT07791979
- Record updated
- 28 August 2026
- Original description
Hypoxemia is the most common adverse event during propofol sedation for gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD) due to diminished pulmonary reserve. Although high-flow nasal cannula (HFNC) oxygenation has been shown to effectively reduce hypoxemia during sedated endoscopy in obese patients, its application in COPD patients remains an evidence gap, largely owing to the traditional concern that high-concentration oxygen may suppress respiratory drive and exacerbate CO₂ retention. This study aims to investigate whether HFNC can reduce the incidence of hypoxemia during sedated gastrointestinal endoscopy in patients with COPD.Read full original descriptionShow less
High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease: A Single-Arm Simon Two-Stage Study
Hypoxemia is the most common adverse event during propofol sedation for gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD) due to diminished pulmonary reserve. Although high-flow nasal cannula (HFNC) oxygenation has been shown to effectively reduce hypoxemia during sedated endoscopy in obese patients, its application in COPD patients remains an evidence gap, largely owing to the traditional concern that high-concentration oxygen may suppress respiratory drive and exacerbate CO₂ retention. This study aims to investigate whether HFNC can reduce the incidence of hypoxemia during sedated gastrointestinal endoscopy in patients with COPD.
Inclusion: Age ≥18 years; Confirmed diagnosis of chronic obstructive pulmonary disease (COPD); Scheduled for elective sedated gastroenteroscopy (gastroscopy, colonoscopy, or combined gastroscopy and colonoscopy); Expected procedure duration ≤45 minutes; Provision of written informed consent by the participant.
Exclusion: Patients with absolute contraindications to high-flow therapy, including but not limited to confirmed diagnosis of complete upper airway obstruction, basilar skull fracture or nasal bone fracture, pneumothorax, or pneumomediastinum; Known allergy to sedative agents such as propofol; Any other condition deemed by the investigator to make the patient unsuitable for trial participation; American Society of Anesthesiologists (ASA) Physical Status class ≥ IV; Requirement for planned endotracheal intubation; Existing tracheostomy; Confirmed pregnancy or currently breastfeeding; Current participation in another interventional clinical trial.